
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc is making significant strides in developing innovative treatment options for psychiatric disorders, particularly with solid advancements in their clinical-stage assets like ALTO-207 and ALTO-101, which have shown enhanced tolerability and safety profiles compared to existing therapies. The ability of ALTO-207 to achieve higher dosages through a fast titration regimen is expected to improve treatment outcomes for patients suffering from depressive symptoms, thus reinforcing the potential for success in this therapeutic area. Furthermore, the development of new transdermal formulations for ALTO-101 and the promising data from agomelatine studies bolster confidence in the efficacy and safety of Alto's expanding pipeline, leading to enhanced market outlook for its stock.
Bears say
Alto Neuroscience Inc's stock has experienced significant pressure since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a crucial Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative data from ALTO-300. The company still has ongoing clinical trials, including a Phase 2b study in bipolar depression, but these programs are considered high-risk with a low probability of success (POS). Additionally, concerns about the efficacy and safety profile of its product candidates, including common side effects and suboptimal therapeutic outcomes compared to standard treatments, further contribute to a negative outlook.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares